Quince Therapeutics' (QNCX) "Buy" Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Quince Therapeutics (NASDAQ:QNCX - Free Report) in a research report released on Friday,Benzinga reports. They currently have a $4.00 price objective on the stock.

Other equities analysts have also issued reports about the stock. Oppenheimer started coverage on shares of Quince Therapeutics in a research report on Monday, March 24th. They issued an "outperform" rating and a $10.00 price objective for the company. Wall Street Zen cut shares of Quince Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $8.00.

Quince Therapeutics Stock Performance

QNCX traded up $0.23 on Friday, hitting $1.43. The company's stock had a trading volume of 654,736 shares, compared to its average volume of 296,088. The firm has a market cap of $65.02 million, a P/E ratio of -1.15 and a beta of 0.80. The company's 50 day simple moving average is $1.06 and its 200-day simple moving average is $1.43. Quince Therapeutics has a 12 month low of $0.51 and a 12 month high of $2.45. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.10). Analysts forecast that Quince Therapeutics will post -1.21 EPS for the current year.

Institutional Investors Weigh In On Quince Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of QNCX. Anfield Capital Management LLC purchased a new position in Quince Therapeutics in the fourth quarter worth $50,000. Virtu Financial LLC purchased a new position in shares of Quince Therapeutics during the 4th quarter valued at about $55,000. Two Sigma Investments LP purchased a new position in shares of Quince Therapeutics during the 4th quarter valued at about $57,000. Intellectus Partners LLC purchased a new position in shares of Quince Therapeutics during the 1st quarter valued at about $71,000. Finally, Northern Trust Corp lifted its position in Quince Therapeutics by 48.5% in the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company's stock worth $94,000 after buying an additional 16,501 shares during the last quarter. 30.75% of the stock is owned by hedge funds and other institutional investors.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.